AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Ginkgo Bioworks Inc. (DNA)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

11.43

-1.25 (-9.86%)

At close: Feb 20, 2025, 3:59 PM

11.43

0.04%

After-hours: Feb 20, 2025, 07:00 PM EST

undefined% (undefined)

Bid	11.4
Market Cap	656.70M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-12.89
PE Ratio (ttm)	-0.89
Forward PE	n/a
Analyst	Sell

Ask	11.5
Volume	2,139,475
Avg. Volume (20D)	1,528,713
Open	12.57
Previous Close	12.68
Day's Range	11.21 - 12.57
52-Week Range	5.26 - 64.40
Beta	undefined

About DNA

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Bi...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Apr 19, 2021

Employees 1,218

Stock Exchange NYSE

Ticker Symbol DNA

Website https://www.ginkgobioworks.com

Full Company Profile

Analyst Forecast

According to 5 analyst ratings, the average rating for DNA stock is "Sell." The 12-month stock price forecast is $10, which is a decrease of -12.47% from the latest price.

Buy 20.00%

Hold 20.00%

Sell 60.00%

Stock Forecasts

Next Earnings Release

Ginkgo Bioworks Inc. is scheduled to release its earnings on Feb 25, 2025, after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

3 months ago

-4.22%

Ginkgo Bioworks shares are trading higher after th... Unlock content with Pro Subscription

5 months ago

+9.31%

Ginkgo Bioworks shares are trading higher after the company announced it launched a protein LLM and model API build on Google Cloud to accelerate drug development.

News

6 days ago · businesswire.com

DNA from Fiserv Selected by Third Federal as Part of its Digital Transformation

MILWAUKEE--(BUSINESS WIRE)--Fiserv, Inc. (NYSE: FI), a leading global provider of payments and financial services technology, today announced it will deliver digital innovation through the award-winni...

1 week ago · accessnewswire.com

Applied DNA Reports First Quarter Fiscal 2025 Financial Results and Highlights Operational Progress

- Announces Exit of DNA Tagging and Security Products and Services Business Segment - - Workforce Reduction of 20% of Headcount Implemented in January - - GMP Site 1 Facility Complete and Certified fo...

1 week ago · accessnewswire.com

Applied DNA to Report First Quarter Fiscal 2025 Financial Results After Market Close on Thursday, February 13, 2025

Investor Call and Webcast Scheduled for 4:30 P.M ET STONY BROOK, NY / ACCESS Newswire / February 12, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polym...

1 week ago · accessnewswire.com

Applied DNA Reminds Shareholders to Vote Ahead of Special Meeting on February 14

STONY BROOK, NY / ACCESS Newswire / February 11, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today issued a reminder to it...

2 weeks ago · zacks.com

Strength Seen in Ginkgo Bioworks (DNA): Can Its 14.5% Jump Turn into More Strength?

Ginkgo Bioworks (DNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near te...

3 weeks ago · zacks.com

Ginkgo Bioworks (DNA) Upgraded to Strong Buy: Here's What You Should Know

Ginkgo Bioworks (DNA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

3 weeks ago · businesswire.com

Genialis Advances Biomarker Discovery to Reduce Risk in Cancer Drug Development Targeting DNA Damage Response Pathways

BOSTON--(BUSINESS WIRE)-- #ISO27001--Genialis and Debiopharm expand collaboration to develop RNA-based predictive biomarkers for DDR therapies, advancing precision oncology.

1 month ago · businesswire.com

Aldevron Unveils Next-Generation Alchemy™ Cell-Free DNA Technology for Research Grade Applications

FARGO, N.D.--(BUSINESS WIRE)--Aldevron Unveils Next-Generation Alchemy™ Cell-Free DNA Technology for Research Grade Applications.

1 month ago · businesswire.com

KBRA Assigns Preliminary Ratings to Freddie Mac's STACR 2025-DNA1

NEW YORK--(BUSINESS WIRE)-- #creditratingagency--KBRA assigns preliminary ratings to 24 classes from Freddie Mac Structured Agency Credit Risk (STACR®) REMIC 2025-DNA1 Notes, Freddie Mac STACR REMIC T...

2 months ago · zacks.com

All You Need to Know About Ginkgo Bioworks (DNA) Rating Upgrade to Buy

Ginkgo Bioworks (DNA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Load More News